Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Royal Victoria Hospital Selects IH Systems’ RIVA
The Royal Victoria Hospital (RVH) in Barrie, Ontario, has become the first Canadian hospital to order a RIVA System (Robotic IV Automation System) – a self-contained unit for
The Royal Victoria Hospital (RVH) in Barrie, Ontario, has become the first Canadian hospital to order a RIVA System (Robotic IV Automation System) – a self-contained unit for
As part of EPA’s efforts to enhance chemicals management under the Toxic Substances Control Act (TSCA), it has released action plans on four chemicals. EPA administrator, Lisa Jackson,
The study is being conducted by Dr. Rhonda Voskuhl, director of UCLA Multiple Sclerosis Program, UCLA Department of Neurology. Investigators will administer Trimesta along with glatimer acetate (Copaxone),
Tim Freeman, director of operations for Freeman Technology, will again join academics and other industry experts for the next Mixing Consultants course covering aspects of powder characterization. The
The European Commission has notified Lundbeck that it has opened proceedings against the company. The purpose is to identify whether Lundbeck has misused a dominant position or has
Watson Pharmaceuticals has confirmed that its subsidiary, Watson Laboratories, has filed an Abbreviated New Drug Application (ANDA) with the FDA seeking approval to market its levonorgestrel and ethinyl
The company claims that Actemra is the first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody approved to treat RA, and may be used alone or in combination with methotrexate or
Reportedly, the phase 1 trial is an open-label, dose-escalation study evaluating the safety and tolerability of TL32711 in adults with solid tumors or lymphoma refractory to standard therapies.
FX125L is the lead drug candidate in this class, while other BSCIs have been identified as back up molecules or as candidates for development as topical anti-inflammatory agents.
PLX4032 is an oral and targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50% of melanomas and about 8% of all